Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era

•Diffuse large B-cell lymphoma (DLBCL) has a high incidence rate in adults.•About 40% of patients with DLBCL develop refractory or relapse DLBCL, leading to these patients’ death.•Molecular subtyping and prognostic factors can lead to a novel therapeutic approach.•Review of knowledge on prognostic f...

Full description

Saved in:
Bibliographic Details
Published in:Experimental hematology 2023-06, Vol.122, p.1-9
Main Authors: Liang, Xiping, Hu, Renzhi, Li, Qiying, Wang, Chaoyu, Liu, Yao
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Biological Factors - therapeutic use
Cyclophosphamide - therapeutic use
Doxorubicin - therapeutic use
Humans
Lymphoma, Large B-Cell, Diffuse - diagnosis
Lymphoma, Large B-Cell, Diffuse - drug therapy
Prednisone - therapeutic use
Prognosis
Rituximab - therapeutic use
Vincristine - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Diffuse large B-cell lymphoma (DLBCL) has a high incidence rate in adults.•About 40% of patients with DLBCL develop refractory or relapse DLBCL, leading to these patients’ death.•Molecular subtyping and prognostic factors can lead to a novel therapeutic approach.•Review of knowledge on prognostic factors might be useful in clinical practice.
ISSN:0301-472X
1873-2399
DOI:10.1016/j.exphem.2023.03.003